Actinium Pharmaceuticals (Delaware) (ATNM) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Stablecoin Development (SDEV) over the past year, losing 21.1% versus a loss of 88.4%. Over five years, ATNM leads with a -85.6% price change compared with -100.0% for SDEV. Stablecoin Development is the larger company by market cap ($36.9 million vs $33.0 million), about 1.1 times the size.
On valuation, Stablecoin Development trades at a lower trailing P/E (0.2x vs 2.4x for Actinium Pharmaceuticals (Delaware)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | SDEV |
|---|---|---|
| Share price | $1.05 | $0.50 |
| Market cap | $33.01M | $36.90M |
| 1-day change | -1.87% | -10.30% |
| YTD return | -22.79% | -98.23% |
| 1-year return | -21.05% | -88.37% |
| 5-year return | -85.60% | -99.98% |
| P/E ratio (TTM) | 2.44 | 0.19 |
| EPS (TTM) | $0.43 | $2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | — |
| Net income (latest FY) | $-33.89M | $-630.78M |
| Operating margin | -40274.44% | — |
| Net margin | -37652.22% | — |
| 52-week high | $1.72 | $99.75 |
| 52-week low | $0.735 | $0.467 |
| Distance from 52-week high | -38.95% | -99.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +242.86% | — |
| Average volume | 193.83K | 16.98M |
| Shares outstanding | 31.44M | 73.80M |
| Employees | 27 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed SDEV by 67.3 percentage points over the past year.
- Actinium Pharmaceuticals (Delaware) trades at a higher earnings multiple (2.4x vs 0.2x trailing P/E).
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ATNM vs SDEV FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $36.90M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or SDEV?
ATNM returned -21.05% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATNM or SDEV?
SDEV has the lower trailing P/E at 0.2, versus 2.4 for ATNM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Actinium Pharmaceuticals (Delaware) and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.